2024-01-28 03:23:32 ET
Summary
- Establishment Labs' Motiva breast implant device has been approved in China with the company eyeing a U.S. FDA approval later this year.
- The outlook for rebounding growth is positive, although we highlight some areas of current financial weakness.
- 2024 will be a critical year for the stock to confirm long-term market potential.
Establishment Labs Holdings Inc. ( ESTA ), within the medical devices industry, focuses on breast augmentation and breast reconstruction technology. The attraction here is the premium implant that provides patients with a more natural feel, and ultimately a safer, longer-lasting solution compared to alternatives on the market....
Read the full article on Seeking Alpha
For further details see:
Establishment Labs: Catalysts Supporting A Perky Outlook